These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31506292)

  • 1. Effects of Selonsertib in Patients with Diabetic Kidney Disease.
    Chertow GM; Pergola PE; Chen F; Kirby BJ; Sundy JS; Patel UD;
    J Am Soc Nephrol; 2019 Oct; 30(10):1980-1990. PubMed ID: 31506292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
    Loomba R; Lawitz E; Mantry PS; Jayakumar S; Caldwell SH; Arnold H; Diehl AM; Djedjos CS; Han L; Myers RP; Subramanian GM; McHutchison JG; Goodman ZD; Afdhal NH; Charlton MR;
    Hepatology; 2018 Feb; 67(2):549-559. PubMed ID: 28892558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
    J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Rosenkranz S; Feldman J; McLaughlin VV; Rischard F; Lange TJ; White RJ; Peacock AJ; Gerhardt F; Ebrahimi R; Brooks G; Satler C; Frantz RP;
    Lancet Respir Med; 2022 Jan; 10(1):35-46. PubMed ID: 34425071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
    Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model.
    Badal SS; Al Tuhaifi T; Yu YF; Lopez D; Plato CT; Joly K; Breckenridge DG; Yang HC; Liles JT; Fogo AB
    Kidney360; 2022 Jul; 3(7):1169-1182. PubMed ID: 35919527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
    Hanrahan JP; de Boer IH; Bakris GL; Wilson PJ; Wakefield JD; Seferovic JP; Chickering JG; Chien YT; Carlson K; Cressman MD; Currie MG; Milne GT; Profy AT
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):59-69. PubMed ID: 33328269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
    Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
    Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Allopurinol on the Progression of Chronic Kidney Disease.
    Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; de Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW;
    N Engl J Med; 2020 Jun; 382(26):2504-2513. PubMed ID: 32579811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease.
    Lin JH; Zhang JJ; Lin SL; Chertow GM
    Nephron; 2015; 129(1):29-33. PubMed ID: 25531162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
    Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu CC; Liu J; Pong A; Cannon CP;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1345-1354. PubMed ID: 34497110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
    de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
    Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
    Wanner C; Heerspink HJL; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; Hantel S; Woerle HJ; Broedl UC; von Eynatten M; Groop PH;
    J Am Soc Nephrol; 2018 Nov; 29(11):2755-2769. PubMed ID: 30314978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects.
    Nelson CH; Etchevers K; Yi S; Breckenridge D; Hepner M; Patel U; Ling J; Mathias A
    Clin Pharmacokinet; 2020 Sep; 59(9):1109-1117. PubMed ID: 32333325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.
    Heerspink HJL; Perkovic V; Tuttle KR; Pergola PE; Mahaffey KW; Patel UD; Ishida JH; Kuo A; Chen F; Kustra R; Petrovic V; Rossing P; Kashihara N; Chertow GM
    J Am Soc Nephrol; 2024 Jul; ():. PubMed ID: 39018154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ; Chiew Y; Ahmad B; Kadir KA
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
    Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
    Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):131-138. PubMed ID: 31189509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
    Tuttle KR; Brosius FC; Adler SG; Kretzler M; Mehta RL; Tumlin JA; Tanaka Y; Haneda M; Liu J; Silk ME; Cardillo TE; Duffin KL; Haas JV; Macias WL; Nunes FP; Janes JM
    Nephrol Dial Transplant; 2018 Nov; 33(11):1950-1959. PubMed ID: 29481660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.